Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

Plain-language summary

Objectives To determine the neuropathological load in the living brain of nondemented adults with Down syndrome using positron emission tomography with 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) and to assess the influence of age and cognitive and behavioral functioning. For reference, [(18)F]FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants. Design Cross-sectional clinical study. Participants Volunteer sample of 19 persons with Down syndrome without dementia (mean age, 36.7 years), 10 patients with Alzheimer disease (mean age, 66.5 years), and 10 controls (mean age, 43.8 years). Main outcome measures Binding of [(18)F]FDDNP in brain regions of interest, including the parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus, and the average of all regions (global binding). Results The [(18)F]FDDNP binding values were higher in all brain regions in the Down syndrome group than in controls. Compared with the Alzheimer disease group, the Down syndrome group had higher [(18)F]FDDNP binding values in the parietal and frontal regions, whereas binding levels in other regions were comparable. Within the Down syndrome group, age correlated with [(18)F]FDDNP binding values in all regions except the posterior cingulate, and several measures of behavioral dysfunction showed positive correlations with global, frontal, parietal, and posterior cingulate [(18)F]FDDNP binding. Conclusions Consistent with neuropathological findings from postmortem studies, [(18)F]FDDNP positron emission tomography shows high binding levels in Down syndrome comparable to Alzheimer disease and greater levels than in members of a control group. The positive associations between [(18)F]FDDNP binding levels and age as well as behavioral dysfunction in Down syndrome are consistent with the age-related progression of Alzheimer-type neuropathological findings in this population.

What this study adds

Evidence grade: Low

This is a cross-sectional study of 19 participants. This small cross-sectional study found higher brain binding of a PET tracer in adults with Down syndrome than in controls, and higher binding in some brain regions than in people with Alzheimer disease. It does not show whether this tracer signal predicts later dementia, and it offers no treatment or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Nelson, L. D., Siddarth, P., Kepe, V., Scheibel, K. E., Huang, S. C., Barrio, JR., et al. (2011). Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome. Archives of neurology. https://doi.org/10.1001/archneurol.2011.104

Vancouver

Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, et al. Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome. Archives of neurology. 2011. doi:10.1001/archneurol.2011.104. PMID: 21670401.

BibTeX

@article{nelson2011-21670401,
  author  = {Nelson, L. D. and Siddarth, P. and Kepe, V. and Scheibel, K. E. and Huang, S. C. and Barrio, JR. and Small, G. W.},
  title   = {{Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome}},
  journal = {Archives of neurology},
  year    = {2011},
  doi     = {10.1001/archneurol.2011.104},
  pmid    = {21670401},
  url     = {https://doi.org/10.1001/archneurol.2011.104}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This small cross-sectional study found higher brain binding of a PET tracer in adults with Down syndrome than in controls, and higher binding in some brain regions than in people with Alzheimer disease. It does not show whether this tracer signal predicts later dementia, and it offers no treatment or prevention.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Archives of neurology)
Journal's citation record 3 / 4 Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 1 / 4 19 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 72 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.2 citations a year over 17 year(s) since 2011
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 9 other studies in this library
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Gary W. Small: h-index 72 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, Los Angeles: institution h-index 1,923 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21670401)
Free to read 0 / 2 Behind a paywall — scores zero
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →